<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03001817</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-301</org_study_id>
    <nct_id>NCT03001817</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function</brief_title>
  <official_title>A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and &lt;2000 mg/dL and Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients&#xD;
      with fasting high triglyceride levels ≥500 mg/dL and &lt;2000 mg/dL and normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Actual">June 24, 2019</completion_date>
  <primary_completion_date type="Actual">June 24, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Remnant Cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo A1</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Non-HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Total Cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in LDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo A2</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo B</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo B48</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo B100</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo C2</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo C3</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apo E</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in hsCRP</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Fasting TG</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Remnant Cholesterol</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo A1</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Non-HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in TC</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in LDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in FFAs</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo A2</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo B</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo B48</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo B100</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo C2</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo C3</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Apo E</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in FGF21</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in hsCRP</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Severe Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>12 Week Efficacy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>K-877 or placebo comparator twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 Week Extension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877</intervention_name>
    <arm_group_label>12 Week Efficacy</arm_group_label>
    <arm_group_label>40 Week Extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>40 Week Extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for K-877)</intervention_name>
    <arm_group_label>12 Week Efficacy</arm_group_label>
    <arm_group_label>40 Week Extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Fenofibrate)</intervention_name>
    <arm_group_label>40 Week Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and willing to comply with all study requirements and procedures&#xD;
             throughout the duration of the study and give written informed consent;&#xD;
&#xD;
          2. Aged ≥18 years;&#xD;
&#xD;
          3. Patients receiving moderate- or high-intensity statin therapy must meet one of the&#xD;
             following criteria¹ unless they have any exceptional conditions (see inclusion&#xD;
             criterion 4):&#xD;
&#xD;
               1. Aged ≥21 years with clinical atherosclerotic cardiovascular disease (ASCVD)&#xD;
                  (history of acute coronary syndrome or myocardial infarction, stable or unstable&#xD;
                  angina, coronary or other arterial revascularization, stroke, transient ischemic&#xD;
                  attack (TIA) presumed to be of atherosclerotic origin, or peripheral arterial&#xD;
                  disease or revascularization), on a high-intensity statin (or moderate-intensity&#xD;
                  statin if not a candidate for high-intensity statin due to safety concerns);&#xD;
&#xD;
               2. Aged ≥21 years with a history of LDL-C ≥190 mg/dL, which is not due to secondary&#xD;
                  modifiable causes, on a high-intensity statin (or moderate-intensity statin if&#xD;
                  not a candidate for high-intensity statin due to safety concerns);&#xD;
&#xD;
               3. Aged 40 to 75 years, inclusive, without clinical ASCVD but with diabetes and a&#xD;
                  history of LDL-C of 70 to 189 mg/dL, inclusive, on a moderate- or high-intensity&#xD;
                  statin; or&#xD;
&#xD;
               4. Aged 40 to 75 years, inclusive, without clinical ASCVD or diabetes, with a&#xD;
                  history of LDL-C of 70 to 189 mg/dL, inclusive, with estimated 10-year risk for&#xD;
                  ASCVD of ≥7.5% by the Pooled Cohort Equation on a moderate- or high-intensity&#xD;
                  statin;&#xD;
&#xD;
          4. Patients currently on a low-intensity statin or not on a statin, must meet one of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Patient does not meet any criteria for moderate- or high-intensity statin therapy&#xD;
                  listed above (see inclusion criteria, criterion 3.a. through 3.d.);&#xD;
&#xD;
               2. Patient does meet one or more criteria for moderate- or high-intensity statin&#xD;
                  therapy listed above (see inclusion criteria 3.a. through 3.d.); but the patient&#xD;
                  is not a candidate for moderate or high-intensity statin due to safety concerns,&#xD;
                  or due to partial or complete statin intolerance; or&#xD;
&#xD;
               3. Patient does meet one or more criteria for moderate- or high intensity statin&#xD;
                  therapy listed above (see inclusion criteria 3.b. through 3.d., except for 3.a.);&#xD;
                  but the patient is not a candidate for moderate or high-intensity statin for&#xD;
                  primary prevention after considering individual risk evaluation (e.g. current LDL&#xD;
                  C ≤70mg/dL) and patient preference;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who will require lipid-altering treatments other than study drugs (K-877 or&#xD;
             fenofibrate), statins, ezetimibe, or PCSK9 inhibitors during the course of the study.&#xD;
             These include bile acid sequestrants, non-study fibrates, niacin (&gt;100 mg/day),&#xD;
             omega-3 fatty acids (&gt;1000 mg/day), or any supplements used to alter lipid metabolism&#xD;
             including, but not limited to, red rice yeast supplements, garlic supplements, soy&#xD;
             isoflavone supplements, sterol/stanol products, or policosanols;&#xD;
&#xD;
          2. Body mass index (BMI) &gt;45 kg/m2 at Visit 1 (Week -8 or Week -6);&#xD;
&#xD;
          3. Patients with type 1 diabetes mellitus;&#xD;
&#xD;
          4. Patients with newly diagnosed (within 3 months prior to Visit 2 [Week -2]) or poorly&#xD;
             controlled type 2 diabetes mellitus (T2DM), defined as hemoglobin A1c &gt;9.5% at Visit 1&#xD;
             (Week -8 or Week -6);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Research Associates, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahaba Research, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyett Health Services Inc</name>
      <address>
        <city>Hamilton</city>
        <state>Alabama</state>
        <zip>35570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longwood Research - Saadat Ansari, MD, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terence T. Hart, MD</name>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <zip>35674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrowhead Health Centers</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research Institute, LLC</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Arizona, LLC</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch - Little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucita M. Cruz, MD., Inc.</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research Collaborative</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALL Medical Research, LLC</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S &amp; W Clinical Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Impotence Treatment Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMPM Research Clinic</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Cardiovascular Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Solutions LLC. - Pembroke Pines</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center of Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Associates, Inc</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research - Savannah, GA</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solaris Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research - Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lemah Creek Clinical Research</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koch Family Medicine</name>
      <address>
        <city>Morton</city>
        <state>Illinois</state>
        <zip>61550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Anderson and Madison County, Inc</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network - Avon Clinical Research Department</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buynak Clinical Research, P.C.</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Broadway Clinic</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic - Cardiovascular Services</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205-1138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Group of Lexington, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Integrity LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC - Northshore</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management LLC - Southshore</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, LLC - West Monroe, LA</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Cardiovascular Specialist</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aa Mrc, Llc</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David M. Headley, MD P.A.</name>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <zip>39150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consult and Research Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Clinical Research, Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Endocrinology Clinical Research Center - Henderson</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Research Center, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeshore Primary Care Associate</name>
      <address>
        <city>Hamburg</city>
        <state>New York</state>
        <zip>14075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Hudson Medical Research, PLLC - Hopewell Junction</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Hudson Medical Research, PLLC - New Windsor</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchard Park Family Practice</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrinology Consultants, P.C.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd. - Auburn</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Research Associates, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research - Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rama Research LLC</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAS Health Ltd</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Group, LLC</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research, LLC - Willoughby Hills</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Central PA, LLC</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harleysville Medical Associates</name>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard M.Kastelic MD and Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green and Seidner Family Practice Associates</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Medical Research, LLC</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeGarmo Institute Of Medical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC - State</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Smyrna, TN</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Innovation Research Group</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT-AACT, LLC, dba Discovery Clinical Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research, LLC - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System - Dallas VA Medical Center (DVAMC)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academy of Diabetes, Thyroid and Endocrine, P.A.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Northwest Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Southwest Houston Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grace Research, LLC - Huntsville, TX</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research, LLC</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Katy</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMC Science</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT - McAllen Primary Care, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Premier Internal Medicine</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bandera Family HealthCare Research, LLC (BFHC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exemplar Research Inc. - Fairmont, WV</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists, LLC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest Regional Hospital</name>
      <address>
        <city>Brest</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Center of Cardiology</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grodno University Hospital</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #10</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mogilev Regional Medical and Diagnostic Center</name>
      <address>
        <city>Mogilev</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Diamedical 2013 OOD</name>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveti Georgi - Clinic of Cardiology</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Bratan Shukjerov</name>
      <address>
        <city>Smolyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD</name>
      <address>
        <city>Smolyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Orfey OOD</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipidova poradna</name>
      <address>
        <city>Bilina</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicus Services SRO</name>
      <address>
        <city>Brandýs nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace pro choroby srdce a cev</name>
      <address>
        <city>Praha 10</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologicka klinika 2. LF UK a FN Motol</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie</name>
      <address>
        <city>Trutnov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Nina Zemkova s.r.o. Interni Ambulance</name>
      <address>
        <city>Uherské Hradište</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Ajara LLC</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic LJ Ltd</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleksandre Aladashvili Clinic - LLC</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Archangel St Michael Multiprofile Clinical Hospital Ltd</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center by Academician G. Chapidze Ltd</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Cardiology Ltd</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Kakheti - Caraps Medline LLC</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Kakheti - Telavi Referral Hospital LLC</name>
      <address>
        <city>Telavi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Gyogyszervizsgalo Kozpont Kft</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Balatongyorok</name>
      <address>
        <city>Balatongyorok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BKS Research Kft.</name>
      <address>
        <city>Hatvan</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SALVIA Lekston i Madej s.j.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleTreeClinics Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Salusmed</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICOME Sp. z o.o.</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O</name>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Metabolicznego Pawel Bogdanski</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarska Ewa Krzyzagorska</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinmedica Research Omc Sp z o.o. Sp</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologiczne Pro Corde Sp. z o. o.</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. M.P. Konchalovskiy</name>
      <address>
        <city>Zelenograd</city>
        <state>Moscow</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First City Clinical Hospital n.a. E.E.Volosevich</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chita State Medical Academy</name>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University based at City Clinical Hospital #7</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Scientific-Research Institute of Complex Problems of Cardiovascular Diseases&quot;</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Alliance&quot;</name>
      <address>
        <city>Kirovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #15 n.a. O.M. Filatov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Outpatient Clinic #3&quot; of Russian Federation President's Management Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Cardiology - Department of Atherosclerosis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Cardiology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental Private Healthcare Institution &quot;Scientific Clinical Centre of Open Joint-Stock Company Russian Railways&quot; (JSC &quot;RZD&quot;)</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.2</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RC Medical LLC</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Physiology and Fundamental Medicine</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical University based at City Clinical Hospital #1</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical-diagnostic center &quot;Zdorovye&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov-on-Don City Hospital of Emergency Care</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioTechService LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Complex JSC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;MedPomosch&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Technologies LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University named after I.I. Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City hospital #38 n.a. N.A. Semashko</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Cardiology Dispensary</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University n. a. V.I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Healthcare Institution &quot;City Pokrovskaya Hospital&quot;, Cardiology Departmen</name>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultative Diagnostic Center with Out-patient Clinic</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk National Research Medical Center of Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Autonomous Institution of healthcare of the Voronezh region &quot;Voronezh regional clinical consultative and diagnostic centre</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly &quot;Zdorovoe Dolgoletie&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Ukrainian Railways&quot; Kharkiv Railway Clinical Hospital#1 of Branch &quot;Healthcare Center&quot; of PJSC &quot;Ukrainian Railways&quot;, Cardiology Depart #1</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Ukrainian Railways&quot; Kharkiv Railway Clinical Hospital#1 of Branch &quot;Healthcare Center&quot; of PJSC &quot;Ukrainian Railways&quot;, Cardiology Depart #2</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Commercial Enterprise &quot;City Clinical Emergency Hospital n.a. prof. O.I. Meshchaninov&quot; of Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Noncommercial Enterprise &quot;City Clinical Hospital #27&quot; of Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Noncommercial Enterprise &quot;City Outpatient Clinic #9&quot; of Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #1, Urgent Cardiology Department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Treatment and Diagnostic Center &quot;Adonis Plus&quot;&quot;, Outpatient Department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine&quot;, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine&quot;, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;City Clinical Hospital #3 n.a. prof. L.J. Aleinikova&quot;, Cardiology Intensive Therapy Department</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Small Private Enterprise, Medical Centre &quot;Puls&quot;</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;City Clinical Hospital #6&quot;, Therapeutic Department</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <results_first_submitted>June 8, 2022</results_first_submitted>
  <results_first_submitted_qc>November 9, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2022</results_first_posted>
  <disposition_first_submitted>April 22, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 1, 2020</disposition_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: ver.1.0</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03001817/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: ver.2.0</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03001817/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: v1.0</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03001817/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: v2.0</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03001817/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Addendum</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03001817/SAP_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible participants entered a 4- to 6-week lifestyle stabilization period followed by a 2-week TG qualifying period, used to determine eligibility for the study. After confirmation of qualifying fasting TG values, eligible participants entered a 12-week Efficacy Period. Participants who successfully completed the 12-week Efficacy Period were eligible to continue in a 40-week Extension Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>K-877</title>
          <description>Participants randomized to receive K-877 0.2 mg tablets twice daily in the 12-week Efficacy Period continued to receive K-877 0.2 mg tablets twice daily (BID) as well as placebo matching fenofibrate tablets once daily, in the 40-week Extension Period</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Fenofibrate</title>
          <description>Participants randomized to receive placebo matching K-877 0.2 mg tablets BID in the 12-week Efficacy Period received fenofibrate 145 mg tablet once daily and placebo matching K-877 0.2 mg tablet BID in the 40-week Extension Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12 Week Efficacy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>40 Week Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>K-877</title>
          <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo/Fenofibrate</title>
          <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="368"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age (Years)</title>
              <category_list>
                <category>
                  <title>&lt;65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="358"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="810.98" spread="369.284"/>
                    <measurement group_id="B2" value="819.25" spread="414.722"/>
                    <measurement group_id="B3" value="813.73" spread="384.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.00" lower_limit="-72.08" upper_limit="-32.40"/>
                    <measurement group_id="O2" value="-7.97" lower_limit="-44.78" upper_limit="49.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Remnant Cholesterol</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Remnant Cholesterol</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.95" lower_limit="-67.97" upper_limit="-27.64"/>
                    <measurement group_id="O2" value="-3.36" lower_limit="-31.18" upper_limit="39.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in HDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.25" lower_limit="-1.13" upper_limit="40.15"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-8.91" upper_limit="15.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann Method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo A1</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo A1</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="-8.68" upper_limit="11.77"/>
                    <measurement group_id="O2" value="2.13" lower_limit="-5.75" upper_limit="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5443</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Non-HDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Non-HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.07" lower_limit="-31.98" upper_limit="0.73"/>
                    <measurement group_id="O2" value="0.81" lower_limit="-17.14" upper_limit="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann Method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Total Cholesterol</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Total Cholesterol</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.26" lower_limit="-24.95" upper_limit="3.40"/>
                    <measurement group_id="O2" value="1.55" lower_limit="-13.17" upper_limit="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in LDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in LDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.93" lower_limit="0.84" upper_limit="78.12"/>
                    <measurement group_id="O2" value="1.01" lower_limit="-19.83" upper_limit="26.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)</title>
          <units>Percent Chage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.07" lower_limit="-41.64" upper_limit="14.10"/>
                    <measurement group_id="O2" value="10.29" lower_limit="-22.61" upper_limit="71.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo A2</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo A2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.30" lower_limit="0.32" upper_limit="27.06"/>
                    <measurement group_id="O2" value="2.89" lower_limit="-5.99" upper_limit="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo B</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo B</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="-12.71" upper_limit="19.36"/>
                    <measurement group_id="O2" value="3.73" lower_limit="-9.09" upper_limit="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4939</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo B48</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo B48</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.35" lower_limit="-64.59" upper_limit="33.65"/>
                    <measurement group_id="O2" value="22.62" lower_limit="-38.27" upper_limit="138.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo B100</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo B100</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="-12.20" upper_limit="20.48"/>
                    <measurement group_id="O2" value="2.76" lower_limit="-11.55" upper_limit="17.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8371</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo C2</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo C2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-25.01" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.03" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3415</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo C3</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo C3</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.56" lower_limit="-54.84" upper_limit="-16.27"/>
                    <measurement group_id="O2" value="5.11" lower_limit="-17.61" upper_limit="36.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apo E</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apo E</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.48" lower_limit="-43.33" upper_limit="-3.58"/>
                    <measurement group_id="O2" value="0.56" lower_limit="-18.21" upper_limit="37.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.97" lower_limit="37.42" upper_limit="469.14"/>
                    <measurement group_id="O2" value="3.88" lower_limit="-100.26" upper_limit="121.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in hsCRP</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in hsCRP</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" lower_limit="-1.491" upper_limit="0.743"/>
                    <measurement group_id="O2" value="-0.100" lower_limit="-1.273" upper_limit="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7442</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.89" lower_limit="-51.25" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="5.99" lower_limit="-21.19" upper_limit="39.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.32" lower_limit="-37.38" upper_limit="5.09"/>
                    <measurement group_id="O2" value="4.70" lower_limit="-18.69" upper_limit="28.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" lower_limit="-19.85" upper_limit="16.25"/>
                    <measurement group_id="O2" value="1.86" lower_limit="-18.40" upper_limit="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0374</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="-13.54" upper_limit="24.49"/>
                    <measurement group_id="O2" value="2.10" lower_limit="-17.05" upper_limit="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7429</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.50" lower_limit="-0.61" upper_limit="44.88"/>
                    <measurement group_id="O2" value="3.06" lower_limit="-14.55" upper_limit="24.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.24" lower_limit="11.80" upper_limit="87.52"/>
                    <measurement group_id="O2" value="1.04" lower_limit="-15.53" upper_limit="21.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.36" lower_limit="17.64" upper_limit="112.28"/>
                    <measurement group_id="O2" value="0.75" lower_limit="-16.59" upper_limit="22.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.87" lower_limit="12.77" upper_limit="111.62"/>
                    <measurement group_id="O2" value="1.26" lower_limit="-17.93" upper_limit="26.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.08" lower_limit="-10.18" upper_limit="85.81"/>
                    <measurement group_id="O2" value="0.85" lower_limit="-14.11" upper_limit="33.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" lower_limit="-41.65" upper_limit="52.99"/>
                    <measurement group_id="O2" value="1.11" lower_limit="-19.55" upper_limit="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3669</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.88" lower_limit="-56.93" upper_limit="7.48"/>
                    <measurement group_id="O2" value="-0.26" lower_limit="-20.30" upper_limit="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.81" lower_limit="-53.95" upper_limit="-12.17"/>
                    <measurement group_id="O2" value="5.60" lower_limit="-19.62" upper_limit="32.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.68" lower_limit="-39.22" upper_limit="-4.57"/>
                    <measurement group_id="O2" value="4.65" lower_limit="-14.87" upper_limit="24.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.34" lower_limit="-19.80" upper_limit="3.85"/>
                    <measurement group_id="O2" value="2.04" lower_limit="-10.69" upper_limit="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a</title>
        <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a</title>
          <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" lower_limit="-13.44" upper_limit="9.82"/>
                    <measurement group_id="O2" value="1.76" lower_limit="-9.43" upper_limit="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0509</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="0.74" upper_limit="4.31"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.97" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.93" lower_limit="-60.09" upper_limit="-7.54"/>
                    <measurement group_id="O2" value="5.37" lower_limit="-23.57" upper_limit="53.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.58" lower_limit="-73.96" upper_limit="-15.98"/>
                    <measurement group_id="O2" value="7.54" lower_limit="-35.11" upper_limit="103.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.57" lower_limit="-72.83" upper_limit="0.59"/>
                    <measurement group_id="O2" value="7.58" lower_limit="-33.08" upper_limit="47.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="-13.53" upper_limit="18.10"/>
                    <measurement group_id="O2" value="-1.87" lower_limit="-23.39" upper_limit="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0647</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.41" lower_limit="-139.84" upper_limit="596.86"/>
                    <measurement group_id="O2" value="51.43" lower_limit="-213.52" upper_limit="275.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" lower_limit="-109.19" upper_limit="49.33"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-98.28" upper_limit="102.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1399</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.54" lower_limit="0.00" upper_limit="256.61"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0122</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.75" lower_limit="-254.51" upper_limit="468.78"/>
                    <measurement group_id="O2" value="23.85" lower_limit="-200.74" upper_limit="297.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0994</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" lower_limit="-9.72" upper_limit="17.11"/>
                    <measurement group_id="O2" value="-1.07" lower_limit="-12.86" upper_limit="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0904</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>μmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="-0.94" upper_limit="1.45"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-1.28" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4346</p_value>
            <method>non-parametric Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium</title>
        <time_frame>12 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 12.</population>
          <units>μmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-4.31" upper_limit="2.65"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-3.32" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1474</p_value>
            <method>non-parametric Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" lower_limit="-14.34" upper_limit="32.08"/>
                    <measurement group_id="O2" value="-2.42" lower_limit="-18.72" upper_limit="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0054</p_value>
            <method>non-parametric Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.70" lower_limit="-14.70" upper_limit="5.21"/>
                    <measurement group_id="O2" value="0.80" lower_limit="-10.18" upper_limit="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.00" upper_limit="3.26"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.51" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-4.44" upper_limit="2.07"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-2.89" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.78" lower_limit="-69.80" upper_limit="-18.51"/>
                    <measurement group_id="O2" value="8.43" lower_limit="-28.90" upper_limit="70.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.06" lower_limit="-70.30" upper_limit="-20.13"/>
                    <measurement group_id="O2" value="6.71" lower_limit="-28.59" upper_limit="70.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-19.62" upper_limit="22.54"/>
                    <measurement group_id="O2" value="-4.63" lower_limit="-18.43" upper_limit="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2049</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.64" lower_limit="-79.05" upper_limit="-34.09"/>
                    <measurement group_id="O2" value="-11.22" lower_limit="-49.07" upper_limit="57.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.84" lower_limit="-42.29" upper_limit="-4.77"/>
                    <measurement group_id="O2" value="-3.86" lower_limit="-22.83" upper_limit="19.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.79" lower_limit="-47.69" upper_limit="-5.64"/>
                    <measurement group_id="O2" value="-4.49" lower_limit="-25.49" upper_limit="23.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.90" lower_limit="7.30" upper_limit="62.27"/>
                    <measurement group_id="O2" value="-0.49" lower_limit="-21.23" upper_limit="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="-15.39" upper_limit="20.43"/>
                    <measurement group_id="O2" value="2.47" lower_limit="-11.55" upper_limit="14.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9117</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>K-877 0.2 mg tablet BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo matching K-877 0.2 mg tablet BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.84" lower_limit="-44.79" upper_limit="-3.68"/>
                    <measurement group_id="O2" value="7.50" lower_limit="-13.29" upper_limit="35.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hodges-Lehmann method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Fasting TG</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Fasting TG</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.93" lower_limit="-73.76" upper_limit="-31.97"/>
                    <measurement group_id="O2" value="-55.45" lower_limit="-68.95" upper_limit="-28.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Remnant Cholesterol</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Remnant Cholesterol</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.98" lower_limit="-70.63" upper_limit="-26.55"/>
                    <measurement group_id="O2" value="-49.11" lower_limit="-67.45" upper_limit="-21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in HDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in HDL-C</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65" lower_limit="-1.27" upper_limit="39.29"/>
                    <measurement group_id="O2" value="19.35" lower_limit="3.03" upper_limit="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo A1</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo A1</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="-8.59" upper_limit="10.42"/>
                    <measurement group_id="O2" value="3.48" lower_limit="-3.42" upper_limit="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Non-HDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Non-HDL-C</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.24" lower_limit="-32.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-15.71" lower_limit="-29.85" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in TC</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in TC</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.84" lower_limit="-25.37" upper_limit="1.61"/>
                    <measurement group_id="O2" value="-9.93" lower_limit="-23.08" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in LDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in LDL-C</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.15" lower_limit="2.04" upper_limit="70.59"/>
                    <measurement group_id="O2" value="36.84" lower_limit="1.38" upper_limit="78.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in FFAs</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in FFAs</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.08" lower_limit="-40.81" upper_limit="18.60"/>
                    <measurement group_id="O2" value="-13.64" lower_limit="-38.15" upper_limit="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo A2</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo A2</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="-2.44" upper_limit="22.58"/>
                    <measurement group_id="O2" value="12.31" lower_limit="0.00" upper_limit="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo B</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo B</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="-12.65" upper_limit="19.85"/>
                    <measurement group_id="O2" value="2.46" lower_limit="-12.68" upper_limit="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo B48</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo B48</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.04" lower_limit="-56.90" upper_limit="68.32"/>
                    <measurement group_id="O2" value="-5.22" lower_limit="-48.40" upper_limit="84.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo B100</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo B100</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="-13.93" upper_limit="19.77"/>
                    <measurement group_id="O2" value="1.97" lower_limit="-12.66" upper_limit="17.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo C2</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo C2</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.70" lower_limit="-30.60" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-1.80" lower_limit="-24.20" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo C3</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo C3</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.70" lower_limit="-58.82" upper_limit="-15.25"/>
                    <measurement group_id="O2" value="-30.77" lower_limit="-51.65" upper_limit="-5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Apo E</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Apo E</title>
          <units>Percent of Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.94" lower_limit="-47.16" upper_limit="-10.64"/>
                    <measurement group_id="O2" value="-30.67" lower_limit="-44.60" upper_limit="-4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in FGF21</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in FGF21</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.20" lower_limit="16.10" upper_limit="545.65"/>
                    <measurement group_id="O2" value="207.50" lower_limit="53.70" upper_limit="499.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in hsCRP</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in hsCRP</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.000" upper_limit="1.400"/>
                    <measurement group_id="O2" value="-0.200" lower_limit="-1.320" upper_limit="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.43" lower_limit="-53.96" upper_limit="5.54"/>
                    <measurement group_id="O2" value="-24.44" lower_limit="-46.64" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.71" lower_limit="-40.18" upper_limit="11.94"/>
                    <measurement group_id="O2" value="-11.70" lower_limit="-32.94" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.28" lower_limit="-22.23" upper_limit="17.29"/>
                    <measurement group_id="O2" value="-3.23" lower_limit="-18.03" upper_limit="28.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" lower_limit="-12.86" upper_limit="25.81"/>
                    <measurement group_id="O2" value="8.23" lower_limit="-15.88" upper_limit="37.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05" lower_limit="2.32" upper_limit="48.91"/>
                    <measurement group_id="O2" value="21.09" lower_limit="-4.00" upper_limit="51.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.52" lower_limit="17.51" upper_limit="95.70"/>
                    <measurement group_id="O2" value="38.99" lower_limit="9.07" upper_limit="82.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.54" lower_limit="21.24" upper_limit="120.44"/>
                    <measurement group_id="O2" value="44.52" lower_limit="8.87" upper_limit="113.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.07" lower_limit="14.25" upper_limit="122.86"/>
                    <measurement group_id="O2" value="42.18" lower_limit="8.41" upper_limit="102.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.63" lower_limit="-7.19" upper_limit="75.36"/>
                    <measurement group_id="O2" value="30.84" lower_limit="-3.26" upper_limit="86.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="-42.86" upper_limit="42.90"/>
                    <measurement group_id="O2" value="4.31" lower_limit="-23.03" upper_limit="45.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.86" lower_limit="-55.96" upper_limit="10.11"/>
                    <measurement group_id="O2" value="-15.38" lower_limit="-48.48" upper_limit="13.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.58" lower_limit="-52.93" upper_limit="-11.22"/>
                    <measurement group_id="O2" value="-27.86" lower_limit="-50.00" upper_limit="-2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.00" lower_limit="-36.55" upper_limit="-6.88"/>
                    <measurement group_id="O2" value="-22.02" lower_limit="-35.80" upper_limit="-3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.54" lower_limit="-18.19" upper_limit="2.06"/>
                    <measurement group_id="O2" value="-8.99" lower_limit="-19.00" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a</title>
        <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a</title>
          <description>Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.58" lower_limit="-12.59" upper_limit="6.5"/>
                    <measurement group_id="O2" value="-3.06" lower_limit="-12.33" upper_limit="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="0.55" upper_limit="4.69"/>
                    <measurement group_id="O2" value="1.56" lower_limit="0.39" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.09" lower_limit="-59.18" upper_limit="-7.46"/>
                    <measurement group_id="O2" value="-30.29" lower_limit="-53.45" upper_limit="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Particles-Large</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.64" lower_limit="-75.46" upper_limit="-10.20"/>
                    <measurement group_id="O2" value="-51.23" lower_limit="-70.89" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.20" lower_limit="-71.10" upper_limit="-1.20"/>
                    <measurement group_id="O2" value="-20.70" lower_limit="-70.4" upper_limit="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-19.00" upper_limit="19.40"/>
                    <measurement group_id="O2" value="3.85" lower_limit="-21.90" upper_limit="21.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.00" lower_limit="-115.00" upper_limit="533.00"/>
                    <measurement group_id="O2" value="213.50" lower_limit="-97.00" upper_limit="572.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" lower_limit="-101.00" upper_limit="48.00"/>
                    <measurement group_id="O2" value="-6.50" lower_limit="-133.00" upper_limit="75.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" lower_limit="0.00" upper_limit="280.00"/>
                    <measurement group_id="O2" value="50.50" lower_limit="0.00" upper_limit="215.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.00" lower_limit="-222.00" upper_limit="420.00"/>
                    <measurement group_id="O2" value="138.00" lower_limit="-187.00" upper_limit="436.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="-11.50" upper_limit="15.46"/>
                    <measurement group_id="O2" value="1.38" lower_limit="-12.57" upper_limit="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>umol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-1.20" upper_limit="1.40"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-1.20" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium</title>
        <time_frame>52 Weeks</time_frame>
        <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium</title>
          <population>Since there were one or multiple records with a baseline value of 0, the percent change cannot be determined for such records. In such cases, the secondary endpoints were evaluated for change from baseline to week 52.</population>
          <units>umol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" lower_limit="-4.80" upper_limit="2.10"/>
                    <measurement group_id="O2" value="-1.15" lower_limit="-4.10" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" lower_limit="-11.19" upper_limit="32.20"/>
                    <measurement group_id="O2" value="6.37" lower_limit="-12.50" upper_limit="30.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.12" lower_limit="-16.22" upper_limit="5.41"/>
                    <measurement group_id="O2" value="-6.70" lower_limit="-16.08" upper_limit="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.00" upper_limit="3.08"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.00" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" lower_limit="-4.49" upper_limit="2.33"/>
                    <measurement group_id="O2" value="-1.11" lower_limit="-3.49" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.01" lower_limit="-70.62" upper_limit="-22.77"/>
                    <measurement group_id="O2" value="-48.29" lower_limit="-65.74" upper_limit="-7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</title>
        <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL &amp; Chylomicron Triglyceride</title>
          <description>Two types of lipoprotein particles were analyzed together as one measurement without distinction.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.38" lower_limit="-71.40" upper_limit="-24.22"/>
                    <measurement group_id="O2" value="-47.69" lower_limit="-65.55" upper_limit="-7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" lower_limit="-18.74" upper_limit="22.40"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-17.24" upper_limit="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.46" lower_limit="-80.92" upper_limit="-32.83"/>
                    <measurement group_id="O2" value="-65.21" lower_limit="-77.40" upper_limit="-38.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.21" lower_limit="-42.91" upper_limit="-6.46"/>
                    <measurement group_id="O2" value="-27.59" lower_limit="-41.20" upper_limit="-6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.63" lower_limit="-48.39" upper_limit="-7.52"/>
                    <measurement group_id="O2" value="-32.36" lower_limit="-46.88" upper_limit="-8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.03" lower_limit="6.73" upper_limit="57.69"/>
                    <measurement group_id="O2" value="24.73" lower_limit="2.50" upper_limit="60.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="-16.67" upper_limit="18.46"/>
                    <measurement group_id="O2" value="-1.76" lower_limit="-13.04" upper_limit="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>K-877</title>
            <description>Participants randomized to receive K-877 0.2 mg BID in the 12-week Efficacy Period continued to receive K-877 0.2 mg BID, as well as placebo matching fenofibrate 145 mg once daily, in the 40-week Extension Period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Fenofibrate</title>
            <description>Participants randomized to receive placebo matching K-877 0.2 mg BID in the 12-week Efficacy Period received fenofibrate 145 mg once daily and placebo matching K-877 0.2 mg BID in the 40-week Extension Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2</title>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.98" lower_limit="-40.38" upper_limit="-0.74"/>
                    <measurement group_id="O2" value="-13.99" lower_limit="-37.76" upper_limit="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 Weeks</time_frame>
      <desc>Treatment-emergent adverse event (TEAE) was defined as any adverse event that occurred for the first time after the first dose of double-blind study drug or existed prior to the first dose and worsened during the post-dosing period.</desc>
      <group_list>
        <group group_id="E1">
          <title>K-877: 12-Week Efficacy</title>
          <description>K-877 0.2 mg Tablets BID&#xD;
Only AEs with onset in the 12-week efficacy period are included.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: 12-Week Efficacy</title>
          <description>Placebo matching K-877 0.2 mg BID&#xD;
Only AEs with onset in the 12-week efficacy period are included.</description>
        </group>
        <group group_id="E3">
          <title>K-877 and Fenofibrate Placebo: 40-Week Extension</title>
          <description>Participants randomized to receive K-877 0.2 mg tablets twice daily in the 12-week Efficacy Period continued to receive K-877 0.2 mg tablets BID, as well as placebo matching fenofibrate 145 mg tablets once daily, in the 40-week Extension Period.&#xD;
Only AEs with onset in the 40-week extension period are included.</description>
        </group>
        <group group_id="E4">
          <title>Fenofibrate and K-877 Placebo: 40-Week Extension</title>
          <description>Participants randomized to receive placebo matching K-877 0.2 mg tablets BID in the 12-week Efficacy Period received fenofibrate 145 mg tablets once daily and placebo matching K-877 0.2 mg tablets BID in the 40-week Extension Period.&#xD;
Only AEs with onset in the 40-week extension period are included.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Operations</name_or_title>
      <organization>Kowa Research Institute, Inc.</organization>
      <phone>919-433-1600</phone>
      <email>CTGResults@KowaUS.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03001817
org study id: K-877-301
nct id: NCT03001817
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients
      with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Remnant Cholesterol
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in HDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo A1
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Non-HDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Total Cholesterol
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in LDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo A2
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo B
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo B48
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo B100
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo C2
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo C3
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Apo E
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in hsCRP
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a
time frame: 12 Weeks
description: Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles
time frame: 12 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large
time frame: 12 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large
time frame: 12 Weeks
measure: Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride
time frame: 12 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
time frame: 12 Weeks
measure: Percent Change From Baseline to Week 52 in Fasting TG
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Remnant Cholesterol
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in HDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo A1
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Non-HDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in TC
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in LDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in FFAs
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo A2
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo B
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo B48
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo B100
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo C2
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo C3
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Apo E
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in FGF21
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in hsCRP
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a
time frame: 52 Weeks
description: Two lipoprotein subclasses, HDL3 and HDL2a, were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles
time frame: 52 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large
time frame: 52 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large
time frame: 52 Weeks
measure: Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride
time frame: 52 Weeks
description: Two types of lipoprotein particles were analyzed together as one measurement without distinction.
measure: Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1
time frame: 52 Weeks
measure: Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2
time frame: 52 Weeks
arm group label: 12 Week Efficacy
arm group type: Placebo Comparator
description: K-877 or placebo comparator twice daily for 12 weeks
arm group label: 40 Week Extension
arm group type: Active Comparator
description: K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
intervention type: Drug
intervention name: K-877
arm group label: 12 Week Efficacy
arm group label: 40 Week Extension
intervention type: Drug
intervention name: Fenofibrate
arm group label: 40 Week Extension
intervention type: Drug
intervention name: Placebo (for K-877)
arm group label: 12 Week Efficacy
arm group label: 40 Week Extension
intervention type: Drug
intervention name: Placebo (for Fenofibrate)
arm group label: 40 Week Extension
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Belarus
country: Bulgaria
country: Czechia
country: Georgia
country: Hungary
country: Poland
country: Russian Federation
country: Ukraine
country: United States
responsible party type: Sponsor
mesh term: Hypertriglyceridemia
mesh term: Fenofibrate
provided document: 
provided document: 
provided document: 
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 